Tesamorelin improved cognition in a 20-week trial of 152 older adults

How could tesamorelin affect the brain?

Tesamorelin, a stabilized GHRH analog, acts through the GH/IGF-1 axis, and receptors for growth hormone and IGF-1 sit on neurons, glial cells, endothelial cells, and perivascular cells throughout the brain ^[1].

Growth hormone and IGF-1 are not just body-composition hormones. The GH/IGF-1 axis is implicated in neuronal and dendritic growth, neurotransmission, and the proliferation of neural progenitor cells into new neurons, oligodendrocytes, and astrocytes ^[1]. The axis also appears to support cerebrovascular function, including blood-brain barrier integrity and neurovascular coupling, mechanisms that decline with age alongside GH and IGF-1 output ^[7].

GHRH is the hypothalamic signal that drives pituitary GH release, and its own production falls with age in step with GH and IGF-1 ^[6]⁠^[7]. The hypothesis is coherent: restoring a GHRH signal that has faded with age would partially restore some of what it supported downstream, including in the brain. That is a mechanistic argument, not a clinical result.

What did the tesamorelin cognition trial find?

In a 20-week randomized, double-blind, placebo-controlled trial of 152 older adults, tesamorelin improved executive function, and verbal memory showed benefit in some analyses ^[5].

The Baker trial randomized adults with a mean age of 68, roughly half cognitively healthy and half with MCI, to daily subcutaneous tesamorelin (1 mg) or placebo for 20 weeks. Testing ran at baseline, week 10, week 20, and week 30, after a 10-week washout ^[5].

The effect was present in both the healthy and MCI subgroups but partly attenuated after washout. That pattern suggests active exposure to the peptide, not a lasting rewiring, was doing the work ^[5].

What did the tesamorelin brain chemistry and biomarker substudies show?

A spectroscopy substudy found tesamorelin altered brain neurotransmitter levels ^[4], but a plasma biomarker substudy found no measurable treatment effect on its panel ^[3].

The neurochemical substudy used magnetic resonance spectroscopy in 30 participants from the same trial. GHRH altered brain levels of glutamate and inhibitory transmitters, a plausible neurochemical correlate for the cognitive change rather than proof of a specific pathway ^[4].

The biomarker substudy measured neuronally-derived plasma exosomes in the same cohort. Several AD-related proteins differed by MCI status, but those differences were independent of GHRH treatment: tesamorelin did not measurably shift this particular biomarker panel, even where it shifted cognition ^[3].

How strong is the evidence that tesamorelin improves cognition?

Tesamorelin's one clean positive cognitive result comes from a randomized, double-blind, placebo-controlled trial, and the effect was modest and population-specific ^[5].

That design puts the evidence well above the mechanistic-plausibility and bro-science tiers where most peptide cognition claims live. The limits are just as specific. The effect size in the parent trial was modest, and the population was older adults with an age-declined GH axis, mean age 68, range 55 to 87. The benefit was not uniform: it tracked more strongly in healthy older adults than in those with MCI ^[5].

Does tesamorelin improve cognition in people with HIV?

Tesamorelin produced only a nonsignificant trend toward better neurocognitive performance in a trial of 73 people with HIV and abdominal obesity ^[2].

Participants took tesamorelin at 2 mg daily for 6 months, compared with standard of care, and IGF-1 rose as expected ^[2]. Rising IGF-1 did not correlate with the cognitive change in that trial.

Taken together, the two RCTs say something the marketing skips: tesamorelin does not reliably improve cognition just because it reliably raises IGF-1. The effect is population- and context-dependent, and the one clean positive result comes from adults whose GH axis had already declined with age. For tesamorelin's body-composition record, see what tesamorelin does to visceral fat.

Does tesamorelin improve cognition in healthy younger adults?

None of the trials cited below tested tesamorelin for cognition in healthy younger adults with an age-appropriate GH/IGF-1 axis.

The Baker trial enrolled adults with a mean age of 68 whose somatotropic axis had already declined. The mechanism proposed for benefit is restoration of a deficit, not enhancement of an already-adequate system ^[5]⁠^[6]. A reader already training, sleeping, and eating well, with an age-appropriate GH/IGF-1 axis, is not the person in whom this benefit was demonstrated.

None of the studies cited below tests whether pushing IGF-1 higher in someone with normal, age-appropriate output produces any cognitive gain. The HIV trial's null result in a metabolically different, non-elderly population is a reason for caution rather than optimism about extending the finding further ^[2].

Do CJC-1295, ipamorelin, or sermorelin have the same cognitive evidence?

CJC-1295, ipamorelin, and sermorelin do not share tesamorelin's cognitive evidence: the positive trial used prescription tesamorelin, an FDA-approved, standardized GHRH analog.

Compounded CJC-1295, ipamorelin, or sermorelin blends are typically marketed for "mental clarity." None of the studies cited below is a randomized cognitive trial of those compounds, and citing the tesamorelin data to support them is a molecule swap the trials do not license.

For those molecules' own records, see what studies show for CJC-1295 and ipamorelin and how sermorelin's evidence compares with tesamorelin's.

How was tesamorelin dosed in the cognition trial?

Participants self-injected tesamorelin 1 mg subcutaneously at bedtime, daily for 20 weeks ^[5].

Monitoring included oral glucose tolerance testing before and after the intervention, because GHRH analogs affect glucose handling ^[5]. The GH/IGF-1 axis interacts with insulin sensitivity, a real consideration for someone metabolically healthy and not GH-deficient who raises GH/IGF-1 signaling anyway.

None of the studies cited below reports the full adverse-event profile in numeric terms. Specific side-effect frequencies quoted elsewhere do not trace to these trials.

What is still unknown about tesamorelin and cognition?

Durability, younger adults, and other secretagogues are the main gaps in tesamorelin's cognitive evidence:

• Durability. Durability past 20 weeks is unknown; the only data point on stopping is a partial reversal after a 10-week washout ^[5].
• Younger adults. None of the trials cited below tested adults under 55 with normal GH/IGF-1 status.
• Deficit dependence. Whether the benefit depends on starting from an age-related deficit, meaning it might not appear, or might carry different risk, in someone starting from normal, is an open question the trials were not designed to answer.
• Other secretagogues. No study cited below tests whether any secretagogue other than tesamorelin produces a comparable cognitive signal.